Economic Evaluation of Cladribine Tablets in Patients With High Disease Activity–Relapsing-Remitting Multiple Sclerosis in the Kingdom of Saudi Arabia [Editor's Choice]



Cladribine tablets are the first short-course oral treatment approved for high disease activity relapsing-remitting multiple sclerosis (HDA-RRMS) across various countries. This analysis assessed the cost-effectiveness of introducing cladribine tablets as a treatment option for patients with high disease activity compared with other HDA-RRMS therapies in the Kingdom of Saudi Arabia (KSA).


The cost-effectiveness model was adapted from the KSA payer’s perspective. Data for the model’s adaptation were retrieved from the literature and validated by key opinion leaders. The comparators considered in the model were alemtuzumab, dimethyl fumarate, fingolimod, interferon beta-1a (subcutaneous and intramuscular) and beta-1b, natalizumab, and teriflunomide. A sensitivity analysis was also performed to assess the robustness of the analysis.


The cost-effectiveness results showed cladribine tablets as the dominant strategy (ie, less costly and more effective) versus all the comparators. The incremental cost and quality-adjusted life-years gained were largely driven by drug acquisition cost and delayed expanded disability status scale progression, respectively. Cladribine tablets showed an 81% to 100% probability of being cost-effective at a threshold of Saudi Riyal 225 326 per quality-adjusted life-years gained against different comparators.


Cladribine tablets are a dominant treatment option for patients with HDA-RRMS from the payer perspective in the KSA.


Saeed Bohlega Ahmed Elboghdady Awatef Al-Johani Koshu Mahajan Majdoline Khalil Mughari Mai Al-Saqa’aby Omneya Mohamed Rola Alarieh Yaser Al Malik

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now